Fractyl Health (GUTS) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Fractyl Health (NASDAQ:GUTS) is expected to report its Q2 2025 earnings on August 13th, anticipating a loss of ($0.37) per share.
• The company reported a significant negative net margin of 73,864.52% in its last quarterly results and analysts predict a $-2 EPS for the current and next fiscal year.
• Canaccord Genuity Group has issued a "buy" rating on Fractyl Health with a price target of $12.00, indicating positive growth expectations.

Fractyl Health (NASDAQ:GUTS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 12th. Analysts expect Fractyl Health to post earnings of ($0.37) per share for the quarter.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.49) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.49). Fractyl Health had a negative return on equity of 228.66% and a negative net margin of 73,864.52%. On average, analysts expect Fractyl Health to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fractyl Health Stock Down 1.2%

Fractyl Health stock traded down $0.01 during mid-day trading on Friday, hitting $0.96. The company had a trading volume of 983,712 shares, compared to its average volume of 974,464. Fractyl Health has a 12 month low of $0.83 and a 12 month high of $3.72. The company has a market capitalization of $47.09 million, a PE ratio of -0.52 and a beta of 1.66. The stock's 50 day moving average price is $1.78 and its two-hundred day moving average price is $1.58. The company has a current ratio of 2.50, a quick ratio of 2.50 and a debt-to-equity ratio of 4.61.

Institutional Trading of Fractyl Health

A hedge fund recently raised its stake in Fractyl Health stock. Woodline Partners LP lifted its holdings in shares of Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) by 47.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 516,921 shares of the company's stock after buying an additional 165,786 shares during the period. Woodline Partners LP owned approximately 1.06% of Fractyl Health worth $615,000 at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group began coverage on shares of Fractyl Health in a research note on Tuesday, April 15th. They issued a "buy" rating and a $12.00 price target on the stock.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.